Bard Diagnostic's bladder cancer test cleared by FDA:
This article was originally published in Clinica
Executive Summary
Bard Diagnostic Sciences, a division of CR Bard, has received clearance from the FDA to market its BTA stat test in the US. The test detects bladder cancer with the technology found in one-step pregnancy tests. The company estimates that the test could benefit an estimated 48 million smokers in the US. Smokers experience twice the risk of bladder cancer as nonsmokers. Bladder cancer strikes almost 53,000 people in the US each year, and more than 250,000 people are routinely monitored for the disease, estimates the American Cancer Society.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.